Compare FedEx Corporation (FDX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Pfizer Inc — how do they compare? FedEx Corporation trades at $316.39 (market cap $74.78B), while Pfizer Inc trades at $25.26 (market cap $141.46B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| FDX | PFE | |
|---|---|---|
Market Cap | $74.78B | $141.46B |
Sector | Industrials | Health |
52-Week High | $338.75 | $28.56 |
52-Week Low | $174.81 | $23.29 |
Enterprise Value | $104.42B | $192.12B |
Dividend Yield | 1.56% | 6.93% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $313.66, down slightly by 0.03% on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68%, and has beaten EPS estimates in recent quarters. Recent corporate actions include a dividend payment and a $1.4B sale of its supply chain unit to CMA CGM, aimed at streamlining operations.
The outlook for FDX is mixed; analyst consensus is bullish with a $360.27 price target, but technicals and margin pressures pose risks. Investment opportunities lie in cost-cutting initiatives and steady revenue growth, while risks include competitive threats from Amazon and soft shipping demand. The stock's valuation appears reasonable with a P/E of 16.9.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
